Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delayed Tolerance Through Mixed Chimerism in Kidney Transplant Recipients
NCT05900401Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2023
- Primary completion
- Dec 2031
- Modality
- Stem Cell Therapies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of siplizumab, haploidentical bone marrow transplant (Centre Hospitalier Intercommunal Creteil) in kidney transplant rejection, sponsored by Massachusetts General Hospital. Started Oct 2023; status: recruiting.
02
Drugs
siplizumabhaploidentical bone marrow transplant (Centre Hospitalier Intercommunal Creteil)
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT05900401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05900401.